<DOC>
	<DOCNO>NCT00003194</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy peripheral stem cell transplantation treat patient recurrent refractory solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose thiotepa combination carboplatin topotecan peripheral blood stem cell transplantation patient recurrent refractory pediatric solid tumor . - Determine toxicity regimen patient . OUTLINE : This dose escalation study thiotepa . Patients may receive 2 course mobilization comprise cyclophosphamide etoposide filgrastim ( G-CSF ) support peripheral blood stem cell ( PBSC ) collection . Patients receive thiotepa IV 2 hour day 0 1 ; topotecan IV 30 minute day 0-4 ; carboplatin IV 2 hour day 2 3 . Patients also receive G-CSF beginning day 5 , 24-36 hour follow last dose topotecan . PBSC reinfused day 6 ( 36-48 hour follow last dose topotecan ) course therapy . Patients receive 3 course therapy . Cohorts 3-6 patient receive escalate dos thiotepa maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 1 2 year . PROJECTED ACCRUAL : A maximum 24 patient accrue study .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory pediatric solid tumor Bone marrow metastasis allow PATIENT CHARACTERISTICS : Age : 1 30 Performance status : 02 Life expectancy : At least 2 month Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 ( transfusion independent ) Hemoglobin least 10 g/dL ( RBC transfusion allow ) Hepatic : Bilirubin great 1.5 time normal SGOT great 2.5 time normal Renal : Adequate renal function define one following : GFR creatinine clearance Radioisotope GFR Iothalamate least 70 mL/min Cardiovascular : Adequate cardiac function define one following : Ejection fraction least 55 % MUGA Fractional shorten least 28 % echocardiogram Neurologic : Adequate CNS function define : Seizure disorder , present , control anticonvulsant CNS toxicity great grade 2 Other : No uncontrolled infection Not pregnant nursing No allergy platinum compound No history allergy etoposide ( unless mobilization phase require ) PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior immunotherapy At least 1 week since prior cytokine At least 3 month since prior bone marrow peripheral blood stem cell transplantation No concurrent immunomodulator No concurrent cytokine Chemotherapy : At least 3 week ( 6 nitrosourea ) since prior chemotherapy recover No prior thiotepa No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy At least 6 month since prior total body irradiation condition No concurrent radiotherapy great 10 % total liver , lung , bone marrow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>